Targeting CD36 in Treg cells can inhibit the polarization of M2-like macrophages [108], and may also supplement the blocking effect of PD-1 in treatment to offset the failure of tumor-infiltrating T cells [176], and reprogram TME, which may become a potential therapeutic target for clinical intervention in GC [173]. Here, CD36 is linked to neoplasm.